ArticleRadiation oncology journal2026
Clinical outcomes of radiation therapy as an alternative to radical surgery for early-stage rectal cancer.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTotal mesorectal excision (TME) is the standard treatment for early rectal cancer, but radiation therapy (RT) with or without chemotherapy may be considered as an alternative organ-preserving option. This study evaluated the oncologic outcomes, patterns of failure, salvage treatment efficacy, and TME-free survival (TME-FS) following RT without radical surgery after local excision or biopsy in selected patients. MATERIALS AND
methodsWe retrospectively analyzed 40 patients with cT1-2N0 rectal adenocarcinoma who received RT after local excision or biopsy without subsequent radical surgery between 2007 and 2023. Indications for RT included clinical T1 disease with high-risk features, clinical T2 disease, or tumors located close to the anal verge. The median RT dose was 50.2 Gy, and 29 patients received chemotherapy. Survival outcomes, recurrence patterns, salvage treatments, toxicities, and TME-FS were assessed.
resultsThe median follow-up was 38 months. The 5-year overall survival rates were 87.5% for the cT1 group and 85.6% for the cT2 group, and the 5-year cancer-specific survival rate was 100% in both groups. The 5-year recurrence-free survival rates were 79.3% and 62.8%, respectively. Overall, nine patients experienced treatment failure, and four patients ultimately underwent salvage TME. The 5-year TME-FS were 87.5% in the cT1 group and 78.6% in the cT2 group. No grade 2 or higher late toxicities were observed.
conclusionRT without radical surgery may be a feasible treatment option for cT1-2N0 rectal cancer patients who are unsuitable for, or decline, radical surgery. Close surveillance and timely salvage treatment remain essential, particularly for those with cT2 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.